Eli Lilly stock price forecast: $1,050 resistance as LLY rallies 3.25% to $1,021.31

Traders Union
All News
Financial News
Eli Lilly jumps 3.25% amid legal clarity

Highlights

The Supreme Court's decision finalizes Eli Lilly's $220 million Medicaid settlement, clarifying legal risk and removing a significant investor overhang.
Eli Lilly reinforced commercial momentum by sharing positive long-term safety data for its approved Foundayo weight loss drug amid regulatory scrutiny.
LLY remains in a strong uptrend with a high probability of trading between $995 and $1,050, but short-term overbought signals raise near-term pullback risk.

Legal clarity and safety updates drive investor sentiment shift

The Supreme Court's refusal to hear Eli Lilly's appeal finalizes a $220 million judgment related to underreported Medicaid rebates, clarifying the company's legal exposure and removing a key overhang for investors. In parallel, Eli Lilly responded to regulatory requirements by releasing updated long-term safety data for its new FDA-approved Foundayo weight loss drug, addressing market concerns about sustained product safety and supporting ongoing commercial momentum. The company's Q1 revenue reached $19.8 billion, reflecting continued growth through a focused pipeline in obesity, oncology, and cell therapy segments.

Strong upside momentum as technicals flag overbought risk

The short-, medium-, and long-term moving averages for LLY are at $947.80 (SMA-20), $940.09 (SMA-50), and $922.71 (SMA-200) respectively, all positioned below the current price. The Ichimoku Kijun level of $936.67 acts as immediate support. LLY exhibited a gap up from the previous close of $989.13 to today's open at $1,012.00 and is trading near today's high, indicative of strong intraday momentum. MACD and RSI remain in buy territory, while ADX signals moderate trend strength. Oscillators including Stoch RSI, CCI, and the Bull/Bear Power (BBP) indicate overbought conditions, suggesting that a short-term pullback risk exists even as Awesome Oscillator (AO) confirms continued constructive momentum.

Bullish extension likely barring break below near-term support

Looking ahead to the next five trading days, the typical volatility band for LLY is projected to be between $995 and $1,050. The probability of a further price increase remains high, at over 80%, making a decrease less likely in the immediate term. The baseline view is for sideways action within this range, while a bullish move above $1,050 would signal a breakout. Conversely, if the price falls below immediate support at $995, a short-term correction may develop.

Viktoras Karapetjanc, expert at Traders Union, notes that Eli Lilly’s legal overhang has now been resolved, which reinforces investor confidence and offers clarity for forward planning. He sees the company’s proactive regulatory response and strong Q1 revenue as evidence of robust fundamentals and supportive macro conditions. Momentum indicators and price action confirm high market optimism, although a short-term pullback remains possible. "With the Supreme Court case concluded and new products gaining traction, I expect Eli Lilly to maintain upward momentum within the current volatility band and see any dip toward $995 as a buying opportunity."

Previously it was reported that Eli Lilly's obesity drugs, including those featured on the TrumpRx platform were highlighted as part of broader efforts to expand access to discounted prescription medications. With the company now advancing its weight loss portfolio alongside legal clarity and strong earnings momentum, investors should monitor potential breakout scenarios above $1,050 as a signal for renewed upside in the coming sessions.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.